Human medicines European public assessment report (EPAR): Vitrakvi, larotrectinib, Date of authorisation: 19/09/2019, Revision: 18, Status: Authorised
Vitrakvi is a cancer medicine for treating solid tumours with NTRK gene fusion.
Medicine Insights and Treatment Guides
Evidence-aware medicine information, indications, dosing, and safety guidance connected to products currently available on our site.
Human medicines European public assessment report (EPAR): Lumykras, sotorasib, Date of authorisation: 06/01/2022, Revision: 7, Status: Authorised
Lumykras is a cancer medicine used to treat adults with non-small cell lung cancer (NSCLC) when the cancer is advanced, and its cells have a particular genetic change.
